Cyprus

Cyprus

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.7 (0.67 - 0.72) 2019 Modelled IHME
0.72 (0.70 - 0.75) 2018 Modelled IHME
0.74 (0.71 - 0.76) 2017 Modelled IHME
0.74 (0.72 - 0.76) 2016 Modelled IHME
0.74 (0.72 - 0.77) 2015 Modelled IHME
0.75 (0.72 - 0.77) 2014 Modelled IHME
0.76 (0.73 - 0.78) 2013 Modelled IHME
0.77 (0.74 - 0.79) 2012 Modelled IHME
0.78 (0.75 - 0.81) 2011 Modelled IHME
0.79 (0.77 - 0.82) 2010 Modelled IHME
0.8 (0.78 - 0.83) 2009 Modelled IHME
0.82 (0.79 - 0.84) 2008 Modelled IHME
0.83 (0.81 - 0.86) 2007 Modelled IHME
0.85 (0.82 - 0.87) 2006 Modelled IHME
0.86 (0.84 - 0.89) 2005 Modelled IHME
0.88 (0.85 - 0.90) 2004 Modelled IHME
0.89 (0.87 - 0.92) 2003 Modelled IHME
0.91 (0.89 - 0.94) 2002 Modelled IHME
0.93 (0.90 - 0.96) 2001 Modelled IHME
0.95 (0.92 - 0.98) 2000 Modelled IHME
0.97 (0.94 - 1) 1999 Modelled IHME
0.99 (0.96 - 1.02) 1998 Modelled IHME
1.01 (0.98 - 1.04) 1997 Modelled IHME
1.03 (1 - 1.06) 1996 Modelled IHME
1.05 (1.02 - 1.08) 1995 Modelled IHME
1.07 (1.04 - 1.10) 1994 Modelled IHME
1.1 (1.06 - 1.13) 1993 Modelled IHME
1.12 (1.09 - 1.15) 1992 Modelled IHME
1.15 (1.11 - 1.18) 1991 Modelled IHME
1.17 (1.13 - 1.21) 1990 Modelled IHME
1.72 (1.18 - 2.49) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.02 (0.01 - 0.02) 2019 Modelled IHME
0.02 (0.02 - 0.02) 2018 Modelled IHME
0.02 (0.02 - 0.02) 2017 Modelled IHME
0.02 (0.02 - 0.02) 2016 Modelled IHME
0.02 (0.01 - 0.02) 2015 Modelled IHME
0.02 (0.02 - 0.02) 2014 Modelled IHME
0.02 (0.02 - 0.03) 2013 Modelled IHME
0.02 (0.02 - 0.03) 2012 Modelled IHME
0.03 (0.02 - 0.03) 2011 Modelled IHME
0.03 (0.02 - 0.03) 2010 Modelled IHME
0.03 (0.02 - 0.04) 2009 Modelled IHME
0.03 (0.03 - 0.04) 2008 Modelled IHME
0.04 (0.03 - 0.05) 2007 Modelled IHME
0.04 (0.03 - 0.05) 2006 Modelled IHME
0.05 (0.04 - 0.05) 2005 Modelled IHME
0.05 (0.04 - 0.06) 2004 Modelled IHME
0.05 (0.04 - 0.06) 2003 Modelled IHME
0.05 (0.04 - 0.06) 2002 Modelled IHME
0.06 (0.05 - 0.07) 2001 Modelled IHME
0.06 (0.05 - 0.07) 2000 Modelled IHME
0.07 (0.06 - 0.08) 1999 Modelled IHME
0.08 (0.06 - 0.09) 1998 Modelled IHME
0.09 (0.07 - 0.11) 1997 Modelled IHME
0.1 (0.08 - 0.12) 1996 Modelled IHME
0.12 (0.09 - 0.14) 1995 Modelled IHME
0.14 (0.11 - 0.16) 1994 Modelled IHME
0.16 (0.13 - 0.19) 1993 Modelled IHME
0.19 (0.15 - 0.22) 1992 Modelled IHME
0.22 (0.18 - 0.26) 1991 Modelled IHME
0.25 (0.20 - 0.30) 1990 Modelled IHME
0.6 (0.37 - 0.98) 2015 Modelled WHO
Showing out of
Show more

HBV-related death rate

National
Download
Value (per 100,000) Year Type Source
1.23 (0.92 - 1.61) 2019 Modelled IHME
1.22 (0.92 - 1.59) 2018 Modelled IHME
1.2 (0.92 - 1.56) 2017 Modelled IHME
1.2 (0.92 - 1.57) 2016 Modelled IHME
1.21 (0.93 - 1.56) 2015 Modelled IHME
1.2 (0.93 - 1.55) 2014 Modelled IHME
1.19 (0.92 - 1.54) 2013 Modelled IHME
1.18 (0.91 - 1.52) 2012 Modelled IHME
1.18 (0.92 - 1.53) 2011 Modelled IHME
1.2 (0.93 - 1.56) 2010 Modelled IHME
1.21 (0.93 - 1.58) 2009 Modelled IHME
1.22 (0.94 - 1.58) 2008 Modelled IHME
1.24 (0.96 - 1.63) 2007 Modelled IHME
1.26 (0.96 - 1.64) 2006 Modelled IHME
1.27 (0.97 - 1.67) 2005 Modelled IHME
1.28 (0.98 - 1.67) 2004 Modelled IHME
1.32 (1 - 1.73) 2003 Modelled IHME
1.38 (1.04 - 1.81) 2002 Modelled IHME
1.43 (1.08 - 1.90) 2001 Modelled IHME
1.51 (1.13 - 2.03) 2000 Modelled IHME
1.6 (1.19 - 2.16) 1999 Modelled IHME
1.7 (1.27 - 2.31) 1998 Modelled IHME
1.79 (1.33 - 2.45) 1997 Modelled IHME
1.87 (1.39 - 2.55) 1996 Modelled IHME
1.92 (1.40 - 2.67) 1995 Modelled IHME
1.93 (1.39 - 2.72) 1994 Modelled IHME
1.96 (1.39 - 2.77) 1993 Modelled IHME
1.96 (1.39 - 2.80) 1992 Modelled IHME
1.94 (1.36 - 2.75) 1991 Modelled IHME
1.92 (1.34 - 2.69) 1990 Modelled IHME
Showing out of
Show more
Technical notes

HBV-related deaths

National
Download
Value Year Type Source
16 (12 - 21) 2019 Modelled IHME
16 (12 - 21) 2018 Modelled IHME
15 (12 - 20) 2017 Modelled IHME
15 (12 - 20) 2016 Modelled IHME
15 (11 - 19) 2015 Modelled IHME
15 (11 - 19) 2014 Modelled IHME
14 (11 - 18) 2013 Modelled IHME
14 (11 - 18) 2012 Modelled IHME
14 (10 - 18) 2011 Modelled IHME
13 (10 - 18) 2010 Modelled IHME
13 (10 - 17) 2009 Modelled IHME
13 (10 - 17) 2008 Modelled IHME
13 (10 - 17) 2007 Modelled IHME
13 (10 - 17) 2006 Modelled IHME
13 (10 - 17) 2005 Modelled IHME
13 (10 - 17) 2004 Modelled IHME
13 (10 - 17) 2003 Modelled IHME
13 (10 - 17) 2002 Modelled IHME
13 (10 - 18) 2001 Modelled IHME
14 (10 - 19) 2000 Modelled IHME
14 (11 - 20) 1999 Modelled IHME
15 (11 - 21) 1998 Modelled IHME
16 (12 - 21) 1997 Modelled IHME
16 (12 - 22) 1996 Modelled IHME
16 (12 - 23) 1995 Modelled IHME
16 (12 - 23) 1994 Modelled IHME
16 (11 - 23) 1993 Modelled IHME
16 (11 - 23) 1992 Modelled IHME
15 (11 - 22) 1991 Modelled IHME
15 (10 - 21) 1990 Modelled IHME
48 2016 Modelled WHO
Showing out of
Show more
Technical notes

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
11 (8 - 17) 2019 Modelled IHME
11 (8 - 16) 2018 Modelled IHME
11 (8 - 17) 2017 Modelled IHME
11 (8 - 16) 2016 Modelled IHME
11 (8 - 16) 2015 Modelled IHME
11 (8 - 16) 2014 Modelled IHME
12 (8 - 17) 2013 Modelled IHME
12 (8 - 17) 2012 Modelled IHME
12 (8 - 17) 2011 Modelled IHME
12 (8 - 17) 2010 Modelled IHME
12 (8 - 17) 2009 Modelled IHME
12 (8 - 17) 2008 Modelled IHME
12 (8 - 17) 2007 Modelled IHME
12 (8 - 17) 2006 Modelled IHME
12 (8 - 18) 2005 Modelled IHME
12 (9 - 18) 2004 Modelled IHME
13 (9 - 18) 2003 Modelled IHME
13 (9 - 18) 2002 Modelled IHME
13 (9 - 19) 2001 Modelled IHME
13 (9 - 19) 2000 Modelled IHME
13 (9 - 19) 1999 Modelled IHME
14 (10 - 19) 1998 Modelled IHME
14 (10 - 20) 1997 Modelled IHME
14 (10 - 20) 1996 Modelled IHME
14 (10 - 20) 1995 Modelled IHME
14 (10 - 20) 1994 Modelled IHME
14 (10 - 20) 1993 Modelled IHME
14 (10 - 20) 1992 Modelled IHME
14 (10 - 20) 1991 Modelled IHME
14 (10 - 20) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
97 2018 Survey/reported WHO/UNICEF
97 2017 Survey/reported WHO/UNICEF
97 2016 Survey/reported WHO/UNICEF
97 2015 Survey/reported WHO/UNICEF
96 2014 Survey/reported WHO/UNICEF
96 2013 Survey/reported WHO/UNICEF
96 2012 Survey/reported WHO/UNICEF
96 2011 Survey/reported WHO/UNICEF
96 2010 Survey/reported WHO/UNICEF
96 2009 Survey/reported WHO/UNICEF
93 2008 Survey/reported WHO/UNICEF
93 2007 Survey/reported WHO/UNICEF
93 2006 Survey/reported WHO/UNICEF
88 2005 Survey/reported WHO/UNICEF
88 2004 Survey/reported WHO/UNICEF
88 2003 Survey/reported WHO/UNICEF
88 2002 Survey/reported WHO/UNICEF
89 2001 Survey/reported WHO/UNICEF
89 2000 Survey/reported WHO/UNICEF
89 1999 Survey/reported WHO/UNICEF
88 1998 Survey/reported WHO/UNICEF
88 1997 Survey/reported WHO/UNICEF
88 1996 Survey/reported WHO/UNICEF
68 1995 Survey/reported WHO/UNICEF
54 1994 Survey/reported WHO/UNICEF
41 1993 Survey/reported WHO/UNICEF
27 1992 Survey/reported WHO/UNICEF
20 1991 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
1 2017 Survey/reported EMCDDA, 2019
0 (0 - 0) 2015 Survey/reported EMCDDA, 2017
Showing out of
Show more

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
18 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
Source;
HBV elimination goal
Source:
Year of HBV elimination goal
2030
Source:
HBV testing policy
No policy
Source:
HepB birth dose policy
No
Source: WHO
Eligible for HBV generic medicines
Source: MPP
HCV National Action Plan
Source:
HCV elimination goal
Source:
Year of HCV elimination goal
2030
Source:
HCV testing policy
No policy
Source:
Eligible for HCV generic medicines
Source: MPP
At least one needle-syringe exchange program (NSP) operational
Yes
Source: Harm Reduction International
At least one opioid substitution therapy (OST) program operational
Yes
Source: Harm Reduction International
NSP in at least one prison
No
Source: Harm Reduction International
OST in at least one prison
Yes
Source: Harm Reduction International
% of substance use disorder facilities offering hepatitis testing
Some (11-30%)
Source: WHO

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.64 (0.52 - 0.79) 2019 Modelled IHME
0.64 (0.52 - 0.79) 2018 Modelled IHME
0.64 (0.52 - 0.79) 2017 Modelled IHME
0.62 (0.51 - 0.77) 2016 Modelled IHME
0.61 (0.50 - 0.75) 2015 Modelled IHME
0.61 (0.50 - 0.75) 2014 Modelled IHME
0.61 (0.50 - 0.75) 2013 Modelled IHME
0.61 (0.50 - 0.75) 2012 Modelled IHME
0.61 (0.49 - 0.75) 2011 Modelled IHME
0.61 (0.49 - 0.74) 2010 Modelled IHME
0.59 (0.48 - 0.73) 2009 Modelled IHME
0.56 (0.46 - 0.69) 2008 Modelled IHME
0.53 (0.44 - 0.64) 2007 Modelled IHME
0.5 (0.42 - 0.61) 2006 Modelled IHME
0.49 (0.40 - 0.59) 2005 Modelled IHME
0.49 (0.40 - 0.59) 2004 Modelled IHME
0.49 (0.40 - 0.59) 2003 Modelled IHME
0.49 (0.40 - 0.58) 2002 Modelled IHME
0.48 (0.40 - 0.58) 2001 Modelled IHME
0.48 (0.40 - 0.58) 2000 Modelled IHME
0.48 (0.40 - 0.59) 1999 Modelled IHME
0.48 (0.39 - 0.58) 1998 Modelled IHME
0.48 (0.39 - 0.58) 1997 Modelled IHME
0.48 (0.39 - 0.58) 1996 Modelled IHME
0.48 (0.39 - 0.58) 1995 Modelled IHME
0.49 (0.40 - 0.59) 1994 Modelled IHME
0.51 (0.41 - 0.61) 1993 Modelled IHME
0.53 (0.43 - 0.65) 1992 Modelled IHME
0.57 (0.46 - 0.70) 1991 Modelled IHME
0.6 (0.49 - 0.75) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
0.6 (0.50 - 1.90) 2014 Modelled Gower et al, 2014
People who inject drugs (PWID)
Download
Value (%) Year Type Source
49.7 (44.40 - 55) 2014 Modelled Degenhardt L et al, 2017
47.6 (36.40 - 58.90) 2013 Survey/reported EMCDDA
Showing out of
Show more

HCV-related death rate

National
Download
Value (per 100,000) Year Type Source
3.79 (3 - 4.72) 2019 Modelled IHME
3.73 (2.93 - 4.62) 2018 Modelled IHME
3.67 (2.91 - 4.53) 2017 Modelled IHME
3.67 (2.92 - 4.54) 2016 Modelled IHME
3.67 (2.95 - 4.56) 2015 Modelled IHME
3.62 (2.90 - 4.50) 2014 Modelled IHME
3.58 (2.87 - 4.41) 2013 Modelled IHME
3.52 (2.82 - 4.31) 2012 Modelled IHME
3.5 (2.82 - 4.32) 2011 Modelled IHME
3.5 (2.80 - 4.34) 2010 Modelled IHME
3.46 (2.76 - 4.32) 2009 Modelled IHME
3.45 (2.75 - 4.33) 2008 Modelled IHME
3.45 (2.73 - 4.35) 2007 Modelled IHME
3.43 (2.69 - 4.31) 2006 Modelled IHME
3.38 (2.67 - 4.26) 2005 Modelled IHME
3.31 (2.63 - 4.20) 2004 Modelled IHME
3.3 (2.59 - 4.22) 2003 Modelled IHME
3.33 (2.62 - 4.27) 2002 Modelled IHME
3.34 (2.62 - 4.29) 2001 Modelled IHME
3.38 (2.62 - 4.40) 2000 Modelled IHME
3.42 (2.63 - 4.45) 1999 Modelled IHME
3.42 (2.61 - 4.46) 1998 Modelled IHME
3.4 (2.58 - 4.45) 1997 Modelled IHME
3.41 (2.56 - 4.46) 1996 Modelled IHME
3.43 (2.58 - 4.51) 1995 Modelled IHME
3.46 (2.56 - 4.53) 1994 Modelled IHME
3.52 (2.57 - 4.67) 1993 Modelled IHME
3.53 (2.54 - 4.72) 1992 Modelled IHME
3.49 (2.49 - 4.66) 1991 Modelled IHME
3.45 (2.46 - 4.58) 1990 Modelled IHME
Showing out of
Show more
Technical notes

HCV-related deaths

National
Download
Value Year Type Source
50 (39 - 62) 2019 Modelled IHME
48 (38 - 60) 2018 Modelled IHME
47 (37 - 58) 2017 Modelled IHME
46 (37 - 57) 2016 Modelled IHME
45 (36 - 56) 2015 Modelled IHME
44 (35 - 54) 2014 Modelled IHME
43 (34 - 53) 2013 Modelled IHME
41 (33 - 50) 2012 Modelled IHME
40 (32 - 49) 2011 Modelled IHME
39 (31 - 49) 2010 Modelled IHME
38 (30 - 47) 2009 Modelled IHME
37 (30 - 47) 2008 Modelled IHME
36 (29 - 46) 2007 Modelled IHME
35 (28 - 44) 2006 Modelled IHME
34 (27 - 43) 2005 Modelled IHME
33 (26 - 42) 2004 Modelled IHME
32 (25 - 41) 2003 Modelled IHME
32 (25 - 41) 2002 Modelled IHME
31 (24 - 40) 2001 Modelled IHME
31 (24 - 40) 2000 Modelled IHME
31 (24 - 40) 1999 Modelled IHME
30 (23 - 40) 1998 Modelled IHME
30 (23 - 39) 1997 Modelled IHME
29 (22 - 38) 1996 Modelled IHME
29 (22 - 38) 1995 Modelled IHME
29 (21 - 38) 1994 Modelled IHME
29 (21 - 38) 1993 Modelled IHME
29 (20 - 38) 1992 Modelled IHME
28 (20 - 37) 1991 Modelled IHME
27 (19 - 36) 1990 Modelled IHME
38 2016 Modelled WHO
Showing out of
Show more
Technical notes

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
40 (30 - 50) 2019 Modelled IHME
40 (30 - 50) 2018 Modelled IHME
40 (30 - 50) 2017 Modelled IHME
40 (30 - 50) 2016 Modelled IHME
40 (30 - 50) 2015 Modelled IHME
40 (29 - 50) 2014 Modelled IHME
39 (29 - 50) 2013 Modelled IHME
39 (29 - 49) 2012 Modelled IHME
39 (29 - 49) 2011 Modelled IHME
39 (29 - 48) 2010 Modelled IHME
38 (29 - 48) 2009 Modelled IHME
38 (29 - 48) 2008 Modelled IHME
38 (28 - 48) 2007 Modelled IHME
38 (28 - 48) 2006 Modelled IHME
37 (27 - 47) 2005 Modelled IHME
37 (27 - 47) 2004 Modelled IHME
37 (27 - 47) 2003 Modelled IHME
37 (27 - 47) 2002 Modelled IHME
37 (27 - 47) 2001 Modelled IHME
37 (27 - 47) 2000 Modelled IHME
37 (27 - 47) 1999 Modelled IHME
37 (27 - 47) 1998 Modelled IHME
37 (27 - 47) 1997 Modelled IHME
37 (27 - 48) 1996 Modelled IHME
37 (28 - 48) 1995 Modelled IHME
38 (28 - 48) 1994 Modelled IHME
38 (28 - 48) 1993 Modelled IHME
38 (28 - 48) 1992 Modelled IHME
38 (28 - 48) 1991 Modelled IHME
38 (28 - 48) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 2017 Survey/reported EMCDDA, 2019
0 (0 - 0) 2015 Survey/reported EMCDDA, 2017
Showing out of
Show more

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
18 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
Source;
HBV elimination goal
Source:
Year of HBV elimination goal
2030
Source:
HBV testing policy
No policy
Source:
HepB birth dose policy
No
Source: WHO
Eligible for HBV generic medicines
Source: MPP
HCV National Action Plan
Source:
HCV elimination goal
Source:
Year of HCV elimination goal
2030
Source:
HCV testing policy
No policy
Source:
Eligible for HCV generic medicines
Source: MPP
At least one needle-syringe exchange program (NSP) operational
Yes
Source: Harm Reduction International
At least one opioid substitution therapy (OST) program operational
Yes
Source: Harm Reduction International
NSP in at least one prison
No
Source: Harm Reduction International
OST in at least one prison
Yes
Source: Harm Reduction International
% of substance use disorder facilities offering hepatitis testing
Some (11-30%)
Source: WHO

Overview

HBV elimination goal
Year of goal
2030
HCV elimination goal
Year of goal
2030

Prevalence (national)

Modelled

HBV (HBsAg+)
0.7 (%)
2019
(0.67 - 0.72(%))
IHME
HCV (RNA/cAg+)
0.64 (%)
2019
(0.52 - 0.79(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
16
2019
(12 - 21)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
50
2019
(39 - 62)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.02 (%)
2019, latest modelled
(0.01 - 0.02(%))
IHME

Prevalence PWID

HCV
47.60 (%)
2013, survey/surveillance
(36.40 - 58.90(%))
EMCDDA

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
1
2017
EMCDDA, 2019
Eligible for HBV generic medicines
Eligible for HCV generic medicines

Action plan

View all

Elimination champion

Action plans

Resources

Programs

Partners